Characteristics of OAML patients receiving immuno-/chemotherapy as first line therapy (n = 26).

*patient received concomitant radiotherapy of the orbit.
Abbreviations of therapy regimens applied: R-FCM = rituximab, fludarabine, cyclophosphamide, mitoxantrone; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CNOP = rituximab, cyclophosphamide, mitoxantrone, vincristine; R-2CdA = rituximab, cladribine; MCP = melphalan, chlorambucil, prednisone, Zevalin = yttrium-90-ibritumomab tiuxetan.
PS = performance status; bilat. = bilateral, TTP = time to progression; FUP = follow up time; LN(N) = lymph node(s); CR = complete remission; PR = partial remission; SD = stable disease; PD = progressive disease; ND = no data; ANA = antinuclear antibodies, RF = rheumatic factors.